eChapters

Environmental management systems (EMSs) such as ISO 14000 are seen as mechanisms for achieving improvements in environmental performance and for supporting the trade prospects of “clean” firms. The potential advantages of EMSs are clear, but the adoption of ISO 14000 is very recent, and practical issues are emerging, among them the need for an emphasis on performance improvement and for simplification of certification; the potential for regulatory streamlining; and the trade consequences. This chapter outlines the key elements of an EMS and discusses these issues.

The Benefits of an EMS

An environmental management system (EMS) is a structured program of continuous environmental improvement that follows procedures drawn from established business management practices. The concept is straightforward, and the principles can be easily applied, given the necessary support. There has been increasing interest in the potential value of EMS approaches, ofwhich the recently released ISO 14000 series is the most widely known.

The first steps in the control of industrial pollution have been the creation of the necessary regulatory framework and the specification and design of control equipment to reduce emissions. These efforts have been broadly successful in improving the performance of many polluters, but in other cases, investments in pollution equipment are wasted because the equipment is not operated properly. Attention, in the World Bank and elsewhere, is turning to support of regulatory and end-of-pipe approaches through incentives, production efficiencies, and management improvements a range of measures often grouped under the broad banner of cleaner production and eco-efficiency.

Extraction is a process whereby the desired constituents of a plant are removed using a solvent. The primary ways for extraction of organic molecules of interest to biologists and medical investigators involve breaking open the cells. Cell rupturing is carried out in a variety of ways. The method used depends on the type of tissue used. For plant cells grown in cell suspension culture or for plant callus tissue, a French press or a sonicator can be used to break open the cell.

Introduction 
The discovery and introduction of antimicrobial agents to clinical medicine was one of the greatest medical triumphs of the 20th century that revolutionized the treatment of bacterial infections. However, the gradual emergence of populations of antimicrobial resistant pathogenic bacteria, resulting from use, misuse and abuse of antimicrobials has today become a major global health concern. Antibacterial drugs have revolutionized our ability to control bacterial disease, and their clinical availability has led to dramatic decreases in morbidity and mortality. (Walsh and Wright, 2005). As such, these therapeutics underpin modern medicine. Despite the integral role of antibiotics in sustaining our modern lifestyle, they are undervalued in both cost and significance by society. Over the past century, their use has provided strong selective pressure on microorganisms, leading to preferential survival and spread of those harbouring antibiotic resistance mechanisms. Multidrug resistance is now commonplace amongst bacterial pathogens with antibiotic resistance now affecting all antibiotic classes. (Coates et al, 2011). This is particularly worrisome in the case of Gram-negative bacteria (e.g. Pseudomonas aeruginosa and Acinetobacter baumannii) for which treatment options are already limited. The ‘broken’ economics of antibacterial research and development is often quoted as the main reason for the lack of new therapies but the truth is that it is hard to discover new antibacterial drugs, and the science is not sufficiently advanced to allow discovery of efficient and effective drugs. This has led to fears of a ‘post-antibiotic era’ as it has been estimated that 5–20 novel antibacterial drugs need to enter clinical development in order to effectively contend with the current resistance problem. However, given the attrition rate within the existing drug discovery model, at least 200 discovery programmes would be needed in order to achieve this outcome. Hence, new approaches to antibiotic discovery are needed. The antibiotic pipeline The antibiotic pipeline is not what it once was.4 Pharmaceutical companies were once the main provider of novel antibiotic molecules but they largely withdrew in the late 1990s because of the lack of success and low financial returns in bringing new antibacterial drugs to the market.5 The environment of discovering and developing new antibiotics was quite different during the so-called ‘golden era’ of drug discovery. Antibiotics worked remarkably well because resistance was low and physicians had access to a variety of efficacious antibiotics. Antibiotic research and development programmes were inclined to focus on improved pharmacology to achieve less frequent dosing e.g. once a day, rather than innovative new antibiotics. Natural product screening strategies tended to result in rediscovery of compounds rather than finding new ones. There was also no need to consider those natural products with undesirable properties such as toxicity. Today, only a few large companies such as GlaxoSmithKline, Novartis, Merck and Roche are still actively engaged in antibiotic R&D, with many of the original antibiotic provide.The natural world remains the largest source of novel drug scaffolds making this a viable option in the search for new antibiotic compounds. Advances in bacterial culture techniques, molecular biology and metagenomics will make natural product drug discovery easier and more costeffective, obviating these limiting factors. Screening procedures must include whole-bacterial cell assays, addressing the issue of bacterial permeability and efflux early in the discovery process (Shore and Coukell, 2016). Additionally, the generation of training schemes by, and with, pharmaceutical companies that cover all aspects of the pipeline and include natural product drug discovery, are essential and will ensure that expertise is passed on to future researchers. Investment should also be made into the study of previously characterized lead compounds that did not reach the clinic, so called old leads. The reasons that led to these compounds being dropped from further development vary, ranging from financial issues to trial design, dosing problems and toxicity. It may be that there is now sufficiently improved technology and expertise to develop these as safe and efficacious antibacterials. The revival of interest in old leads could also provide an additional source of novel antimicrobials. A freely accessible database of antibiotics that were never developed has recently been launched, Antibiotic with the aim to reduce unnecessary duplication of Pharmaceutical agents such as nanospheres, liposomes, and immunoglobulins for example have been developed which can alter the pharmacodynamics of a compound, act as carriers for sustained or controlled drug release, and for immunization therapy.

Introduction
Antimicrobial resistance (AMR) is a mounting global crisis that threatens public health, food security, and development. The rapid spread of resistant pathogens has rendered many conventional antibiotics ineffective, leading to longer illnesses, increased mortality, and escalating healthcare costs(1)(2). The World Health Organization characterizes AMR as a top-ten global health threat, driven by overuse, misuse, and inadequate dosing of antibiotics. It already kills 700,000 people a year and is expected to kill 10 million people a year by 2050 if nothing is done about it(3). After penicillin was introduced to the market in 1941, the first signs of resistance appeared in staphylococci, streptococci, and gonococci. By 1942, Staphylococcus aureus, which was penicillin-resistant, emerged(4). Drug resistance must be effectively addressed for a few reasons, including public health, economic considerations, and the long-term viability of medicine. Maintaining the effectiveness of existing treatments for infectious diseases is an important objective(5). NDDS technologies have emerged as powerful tools to enhance the delivery, bioavailability, and targeting of antimicrobial agents, potentially reviving older antibiotics, and maximizing the efficacy of novel compounds(6). Parallelly, AI has found impactful applications in biomedical data analysis, drug discovery, and the rational design of therapies by processing complex datasets, predicting resistance patterns, and guiding the creation of new molecules. The integration of AI with NDDS marks a paradigm shift to optimizes delivery systems, guides individualized treatment plans, and advances the field towards precision medicine for infectious diseases (7). This chapter surveys the convergence of these technologies, exploring how AIenhanced NDDS platforms are reshaping the response to AMR. Additionally, it examines diverse AI models and algorithms employed in the prediction, optimisation, and management of drug resistance, enhanced by real-time case studies for thorough comprehension(fig1.).

1. Introduction

Medicinal plants are nature’s priceless gift to human. They have been used all over the world for the treatment and prevention of various ailments particularly in developing countries where infectious diseases are endemic and modern health facilities and services are inadequate. Medicinal principles are present in different parts of the plants such as root, stem, bark, heartwood, leaf, flower, fruit or plant exudates (Thenmozhi et al., 2010). Phytochemicals from medicinal plants serve as lead compounds in drug discovery and design (Sofowora, 2006).

Free radicals are chemical species which contain one or more unpaired electrons, due to which they are highly metastable and cause damage to other molecules by extracting electrons from them in order to attain stability (Chakraborthy and Ghorpade, 2010). Hyper-physiological burden of free radicals causes imbalance in homeostatic phenomena between oxidants and antioxidants in the body. This imbalance leads to oxidative stress that is being suggested as the root cause of aging and various diseases like diabetes, cancer, and liver damage (in severe conditions like cirrhosis and hepatitis) (Wagh et al., 2010).

1. INTRODUCTION

The medicinal plants have been used by humans from the pre-historical times. Traditional medicine based on herbal remedies has always played a key role in the health systems of many countries. In India, the native people are exploiting a variety of herbals for effective curing of various ailments. Medicinal plants are widely used by all sections of the population and country is richly endowed with a wide variety of plants of medicinal value, which represents the great national resource (Alok, 1991).

It is estimated that at least 70 percent of population relay on herbal medicines for primary health care in our country (Holley and Williams, 1996). In India, different classical medicinal systems such as Ayurveda, Siddha and Unani are being practiced in the country and in addition to innumerable local folk medicinal traditions exist. More than 8000 species of wild plants are known to be used in India for the treatment of various health problems (Ved et al., 2000). This rich medicinal wealth is mainly distributed in two biodiversity hotspots that are Eastern Himalayas and Western Ghats. Numerous studies have pointed out that many drugs that are used in commerce have come from folk-use and use of plants by indigenous cultures (Anon, 1994). Medicinal plants form a heterogeneous group in growth, habit, distribution, reproduction, phenology and their ecological requirements.

Introduction
The discovery of antibiotics and their subsequent use in combating infectious diseaseswas amedical breakthroughin the 20th century, as it completely changed the treatment approach to infections in general and bacterial infections in particular. In 1928, Alexander Fleming discovered Penicillin that started the started the so-called “golden age of antibiotic”. However, later in course of time the underuse, overuse and misuse of antibiotics in medical and veterinary practice led toemergence of drug-resistant pathogens resulting in phenomenon called antimicrobial resistance (AMR). In last few decades AMR has evolved silently and now threatening the human and animal health and has acquired the potential to be a next pandemic. AMR develops in a microorganism (e.g., bacteria, viruses, fungi, parasites) when it accumulates genetic changes over time and fails to respond to antibiotic(s) leading to severe illness and mortality due to infection. Although, AMR is an evolutionary event occurring naturally in microbes, but inappropriate use of antibiotics in humans and animal medicine act as key driver to its spread. Global antibiotic consumption increased between 2016 and 2023, with total consumption rising by 16.3% to 34.3 billion defined daily doses (DDDs) in reporting countries and a projected 20.9% increase when extrapolated to nonreporting countries. World Health Organization (WHO) and other authorities have called for coordinated action to address antimicrobial resistance, a threat looming large on horizon. In 2021, there were an estimated 1.14 million deaths attributed directly to Antimicrobial Resistance (AMR), with globally another 4.71 million deaths associated with AMR infections. This dataindicates a significant global health burden, with prophecy that AMR deaths could increase dangerously by 2050 if current trends continue. Global Action Plan (GAP) of the WHO highlights the importance of “One Health approach” calling for the joint action in human health, food production, animals and environmental sectors, to achieve better results. In the year 2015, the WHO initiated the Global Antimicrobial Resistance and Use Surveillance System (GLASS)to collect, analyze and share AMR data received from all countries. The Global Action Plan on AMR lists five strategic objectives to contain AMR viz., 1. optimizing the use of antimicrobials, 2. preventing infections (including the use of vaccines), 3. strengthening surveillance and research, 4. improving awareness and understanding of AMR, and 5. investing in new medical products. Vaccines stimulate the body’s immune system to recognize and attack specific pathogens and thus can prevent AMR through several ways viz., 1. reduce the incidence of infections leading to reduction in morbidity and mortality, 2. vaccines can prevent secondary bacterial infections e.g. Streptococcus pneumoniae after an initial infection with influenza, 3. produce herd immunity, 4. Prevention of infections resulting in decrease in use of antibiotics that reduces development of AMR. Immunotherapeutics can both combat and be complicated by Antimicrobial Resistance (AMR). Other immunotherapies antibodies, and immune-boosting agents can directly fight AMR by preventing infections and reducing the need for antibiotics.

Introduction
Antimicrobial resistance (AMR) constitutes a profound global health crisis, jeopardizing the efficacy of antibiotics and posing a severe threat to the foundation of modern medical practice. The rise of multidrug-resistant (MDR) pathogens, which exhibit resistance to multiple classes of antibiotics, has significantly escalated the global burden of infectious diseases, complicating treatment protocols and increasing morbidity and mortality rates. According to the World Health Organization (WHO), AMR could lead to 10 million deaths annually by 2050 if current trends continue, accompanied by economic losses projected to reach trillions of dollars due to prolonged hospitalizations, increased healthcare costs, and reduced productivity. The traditional antibiotic development pipeline has stagnated, hampered by scientific complexities, high financial costs, and stringent regulatory frameworks, resulting in a critical shortage of novel antimicrobial agents. This necessitates the exploration of innovative strategies to combat AMR and preserve the utility of existing antibiotics. Among these strategies, Crispr-Cas (Clustered Regularly Interspaced Short Palindromic Repeats and Crispr-associated proteins) systems have emerged as a groundbreaking gene-editing platform with transformative potential for addressing AMR. Initially identified as a bacterial adaptive immune mechanism, Crispr-Cas has been repurposed to enable precise targeting of genetic elements, offering novel therapeutic, diagnostic, and environmental solutions. This chapter provides a comprehensive analysis of Crispr-Cas systems in the context of AMR, exploring their molecular mechanisms, diverse applications, current limitations, and future prospects across clinical, agricultural, and environmental domains. By leveraging the precision and programmability of Crispr-Cas, researchers aim to develop targeted interventions that mitigate the spread of resistance while minimizing collateral damage to beneficial microbial communities.

Introduction
AMR is a critical global problem that affects human, environmental, and animal health. AMR is a complex problem; it is necessary to look at it from different disciplines to frame it within the One Health approach [Shrestha,2018].The World Health Organization (WHO) has identified AMR as a top ten global public health threat.Globally, there were an estimated 4.95 million deaths associated with bacterial AMR in 2019, including 1.27 million deaths attributable to bacterial AMR [O’Neill, J. (2016)]. The economic impact is equally alarming. The World Bank projects that AMR could lead to an additional US$ 1 trillion in healthcare costs by 2050, and over US$ 1 trillion in annual gross domestic product (GDP) losses by 2030.The One Health approach is defined as a joint effort of various disciplines that come together to provide solutions for human, animal, and environmental health. AMR is linked to each of these three components due to the irresponsible and excessive use of antimicrobials in various sectors (agriculture, cattle raising, and human medicine). Under the pressure of antimicrobial selection, bacteria acquire resistance genes and mobile genetic elements that can spread to other bacteria of the same or different genus. When bacteria acquire resistance to antimicrobials, they also acquire a greater ability to proliferate in animals, humans, and the natural world. Mismanagement of antimicrobials, inadequate infection control, agricultural debris, contaminants in the environment, and migration of people and animals infected with resistant bacteria facilitate the spread of resistance [Collignon,et.,al,2018]. AMR represents a global public health problem, for which epidemiological surveillance systems have been established, aiming to promote collaborations directed at the well-being of human and ani mal health and the balance of the ecosystem. Several international organizations (The World Organisation for Animal Health [OIE], WHO, and the Food and Agriculture Organization of the United Nations [FAO]) have joined forces to develop a Global Action Plan on Antimicrobial Resistance-WHO. Action taken in this plan included understanding the AMR from surveillance and research. The advisory group established guidelines for AMR surveillance to ensure all countries implement integrated surveillance, which will cover the use and consumption of antimicrobials in the human and animal population. These guide lines will provide a clear understanding of how AMR spreads in different settings and specific areas. It will allow to study the correlation between AMR and antimicrobial use in a different setting (animals, humans, and environment) and to assess the effect of interventions within and between sectors [W.H.O 2015,2017].

Introduction
Animal sector is growing very fast particularly in India as people’s purchasing power is increasing day by day. With increase in income, people’s dietary habit is shifting towards more animal origin products. The use of antibiotics for animal food production is growing very fast and India is the 4th largest country in the world regarding consumption of antibiotics in veterinary and animal husbandry sector. There is urgent need of AMR mitigation strategies to reduce the effect on human and animal health. As per the World Bank AMR can affect the global GDP upto 3.8% by 2050. Most of the countries in the world are very cautious regarding antibiotic residues and rejecting the livestock products which lead to economic loss. Many world agencies/forum such as CodexAMR Guidelines, UN Political Declaration on AMR Guidelines, Global Leaders Group on AMR reiterated judicious use of antibiotics. All-India Network Project on AMR inLivestock and Fisherieswas started in India to reduce the effect of AMR by educational awareness, adoption at field level, surveillance system and diagnosis but it didn’t meet out the desired outcome. Capacity building programmes in the field of AMR by training, reform in curriculum, collaboration from different fields of professionals can mitigate the harmful effect of AMR. According to the Food and Agriculture Organization (FAO), education and training play pivotal roles in translating knowledge into practical implementation, warranting the inclusion of Antimicrobial Use and AMR as integral components in professional education, postgraduate training, and continuing education within the food and agricultural sectors Training Strategies It involve Antimicrobial Stewardship training for healthcare professionals, public awareness campaigns, farmer education, and veterinary training on responsible antimicrobial use. Other critical elements include fostering collaboration through professional networks, building surveillance capacity, utilizing AI-driven tools for better decision-making, and promoting hygiene and infection prevention to reduce infection incidence and the need for antibiotics.
Training for Healthcare Professionals
There is substantial evidence that both healthcare workers and members of the public have knowledge gaps about appropriate use of antibiotics and mechanisms of antibiotic resistance. Surveillance is a prerequisite to estimate the magnitude of the AMR burden and to establish any intervention strategies, such as antimicrobial stewardship. In order to launch successful intervention approaches through cooperative efforts from different stakeholders (e.g., international agencies, human and veterinary medicine sectors, agriculture and animal production industries, and consumers), the existing knowledge gap needs to be addressed first.

Introduction

In the last decade, digitalization has transformed every aspect of life and society, changing almost every area of our day-to day lives. Not just that; the rate of change that is happening is astonishing and only going to accelerate further. From the way, we work and communicate to how we organize our lives, digital tools and technologies are everywhere including the veterinary sector. Veterinarians are recognizing the need to depart “the analog island” and increasingly willing to embrace digital solutions. Undoubtedly, digitalization is crucial when it comes to boosting efficiency and quality in veterinary medicine and delivery of animal healthcare to masses across various geographies and resource poor setups. Uniquely these digital tools helps vets also to focus on the needs of patients and animal owners.

4.1. Classification

The class Aves, also known as birds, is a group of warm-blooded vertebrates characterized by feathers, toothless beaked jaws, laying hard-shelled eggs, a high metabolic rate, a four-chambered heart, and a strong yet lightweight skeleton. Birds are found worldwide and come in a variety of sizes, from the tiny humming bird to the massive ostrich.

The classification of Aves can be broken down into two major subgroups: Palaeognathae and Neognathae.

4.1.1. Palaeognathae: Also known as ratites, these are flightless birds with f lat sterna (breastbones) that lack keels, which are important for flight muscle attachment. Examples of palaeognathae include ostriches, emus, rheas, and kiwis.

The drug conventionally used for sedation is xylazine, which is an alpha-2 agonist (Dugdale, 2010; Rankin, 2015). Dexmedetomidine is the latest drug of the same class used for sedation, and is more specific to alpha2 receptors than xylazine (Ishyama et al., 1995). Doses of 1-2 mg per kg body weight of xylazine (Hall and Clarke, 2001) and upto 20 mcg per kg body weight of dexmedetomidine (Ko, 2013) are required for sedation when used alone (Hall and Clarke, 2001; Rankin, 2015). Similar degrees of sedation could still be achieved at lower doses of xylazine (0.2 to 0.4 mg per kg body weight) and dexmedetomidine (2.5 to 5 mcg per kg) if administered in combination with any opioid drug like hydromorphone / oxymorphone / fentanyl / buprenorphine / butorphanol / nalbuphine / tramadol at their usual doses (Hunt et al., 2013). Another drug - acepromazine, which is a phenothiazine tranquiliser, is used at its doses of 0.01 to 0.05 mg/kg combined with an opioid for achieving sedation (Smith et al., 2001; Dugdale, 2020; Ko, 2013). Combination of an opioid with either a phenothiazine tranquiliser or an alpha2 agonist sedative drug provides neurolept anaesthesia/analgesia (Dugdale, 2020; Rankin, 2015). An anticholinergic drug - glycopyrrolate is administered in combination with acepromazine and opioid to prevent bradycardia (Dyson and James-Davies, 1999). Anticholinergics are generally not recommended with sedative cocktails containing dexmedetomidine, but preferred with sedative cocktails containing xylazine (Congdon et al., 2011; Billah et al., 2017). If sedation is to be achieved with acepromazine alone, higher doses need to be administered where there will be an increase in its dose dependent side effects, and hence not preferred (Simon and Steagall, 2020). Benzodiazepines are another class of sedative drugs, which generally doesn’t provide predictable sedation in animals. Paradoxical excitement is caused in healthy adults when these drugs are used alone (Herron et al., 2008). Predictable sedation is achieved when these drugs are administered in combination with any opioids (KuKanich and Wiese, 2015). Also, benzodiazepines can be combined with an alpha2-opioid combination to enhance the overall sedation (Maze et al., 1992). Various balanced sedative cocktails prepared with the drugs available for a veterinary practitioner in India, are presented. The balanced sedative cocktails are prepared with either

Chemical warfare involves using the toxic properties of chemical substances to kill, injure or incapacitate an enemy.

Chemical warfare is different from the use of conventional weapons or nuclear weapons because the destructive effects of chemical weapons are not primarily due to any explosive force. The offensive use of living organisms (such as anthrax) is considered to be biological warfare rather than chemical warfare; the use of nonliving toxic products produced by living organisms (e.g., toxins such as botulinum toxin, ricin, or saxitoxin) is considered chemical warfare under the provisions of the Chemical Weapons Convention. Under this Convention, any toxic chemical, regardless of its origin, is considered as a chemical weapon unless it is used for purposes that are not prohibited (an important legal definition, known as the General Purpose Criterion)

Introduction

Canine atopic dermatitis (CAD) is a chronic inflammatory skin disease marked by itching (pruritus), redness (erythema), and recurrent infections. While traditionally considered an immune-mediated condition, recent studies highlight the significant role of skin barrier dysfunction in its development. A key aspect of CAD is the compromised skin barrier, which increases permeability to allergens, irritants, and microorganisms, thereby worsening the disease. The skin barrier is a complex, dynamic structure essential for protecting dogs from environmental challenges. The stratum corneum—the outermost layer of the epidermis—serves as a crucial defense against environmental insults, allergens, and pathogens. In dogs with atopic dermatitis, this barrier often becomes impaired, leading to increased transepidermal water loss (TEWL), greater allergen penetration, and secondary infections. This dysfunction both results from and contributes to the condition, creating a self-perpetuating cycle of barrier disruption, inflammation, and immune dysregulation.

Introduction

Mithun (Bos frontalis), or ‘Gayal’ or ‘Eso’ or ‘Sial’ or ‘Sandong’ or ‘Wei’, is a rare bovine species, exclusively found in the northeastern hill region (NEHR) of India at an altitude of 300-3000 m. It plays an important role in the socio-economic and cultural life of indigenous tribes of Arunachal Pradesh, Nagaland, Mizoram and Manipur and is aptly referred to as the ‘Pride of Northeast India’ (Mukherjee et al. 2019). Besides India, mithun population is distributed to China, Bangladesh, Thailand, Bhutan, Myanmar, and Malaysia. The Indian mithun is a medium- to large-sized majestic ruminant with a characteristic jet-black body, an ash-colored forehead, and ‘white stockings’ on all the limbs. This unique animal has a special preference for salt feeding, is a skilled browser even in steep, hilly terrain, and does not need pasture land like cattle. Mithun is primarily reared under a free range system as an important source of lean meat, rich in amino acids, proteins, PUFA, etc. On September 1, 2023, the Food Safety and Standards Authority of India (FSSAI) officially certified the mithun as a food animal (Joshi et al., 2021; Lalchamliani et al., 2024; Ramesh et al., 2024). Compared to milk from other species, mithun milk has much larger quantities of fat, lactose, solids-not fat (SNF), calcium, important vitamins A, D, and E, essential amino acids, and polyunsaturated fatty acids (Devi et al., 2023).

Introduction

Avian medicine is a rapidly growing field, with an increasing number of exotic bird species being kept as pets. However, the unique anatomy, physiology, and behaviour of these birds present several challenges as well as new opportunities for veterinarians and researchers.Now a day’s birds are gaining popularity over dogs and cats because of various reasons listed below:

a. They are more suited in present life style as can be suited well in small spaces.

b. They require low maintenance with relative low cost of maintenance and live longer life.

c. They form very strong bonds with their owners.

Birds can be classified into different families, such as Psittaciformes, Passeriformes, Columbiformes, Piciformes, Anseriformes, Galliformes etc. containing numerous species (>10,000). The first documentation of parrot as a pet was found in Rig Veda, written more than 3000 years ago. Evidence of bird keeping is observed in ancient civilizations of Greece, Rome, China and Egypt. In Greek mythology, Raven (a crow) was mentioned as a symbol of good luck and was associated with God Apollo (God of prophecy). Crows are also considered as ancestors in Hindu mythology and food (pinda) is offered to crows during ritual of paying homage to dead persons. In most of the countries psittacine and passerine birds are preferred as pet birds.

By 2050, the global population is projected to reach approximately 9.8 billion, requiring a 70% increase in food production to meet the growing dietary demands. The livestock sector will play a crucial role in addressing this rising need through sustainable animal production, contributing to food security, poverty alleviation, public health, and food safety. To tackle the challenges posed by population growth and to achieve the United Nations Sustainable Development Goals (SDGs), technological advancements and innovations will be essential in transforming the food and agriculture sectors.

In light of these challenges, Veterinary Services are more critical than ever. They are essential for enhancing livestock health and productivity, ensuring high-quality food that meets safety standards, and mitigating risks associated with animal diseases and public health. Additionally, Veterinary Services must contribute to global efforts in addressing issues such as food security, antimicrobial resistance, climate change, and the depletion of natural resources.

ABSTRACT

Colchicine, one of the most widely used alkaloids is synthesized in Gloriosa species, a plant of great medicinal importance. The seeds, tubers and leaves of six different species of Gloriosa were phytochemically investigated for alkaloids and were found to contain colchicine and colchicoside. These alkaloids were isolated and quantified by HPLC analysis. This is the first report of alkaloids in Gloriosa plantii, Gloriosa lutea, and Gloriosa vuchuria. The colchicine and colchicoside content of the Gloriosa species was found to be organ dependent as there was statistically significant differences (P<0.05) between different organs but not among different species under study. The total alkaloids are organ as well as species dependent as there were statistically significant differences (P<0.05) between all the species as well as organs of different species of Gloriosa under study and its organs.

A new buzz-word is rapidly spreading through the manufacturing and analytical environment. Discussions on the application of Non Invasive Research namely the Near Infrared (NIR) Spectroscopy are often found on the agenda of production, project, and technical and even board meetings. Engineers and chemists are confronted more frequently with the challenge to decide whether a NIR instrument will be the solution to their production quality control and other analytical problems. Are there really amazing machines that can determine protein, fat, moisture, fibre, starch, nicotine, alcohol, sugar, amino acids and whatever analyses you require on any product from foodstuff to fertilizer and animal feeds in less than a minute and so simple to operate that even the unskilled labourer can handle it? In this article we will endeavor to answer the questions that often crop up in the evaluation of NIR as an analytical technique towards Natural Products.